Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement project

Hospital admissions to treat fluid overload are common in patients with both heart failure and chronic kidney disease (CKD-HF). This is a population with high levels of frailty. Recurrent hospital admissions are costly to both patients and healthcare systems. We designed a proof-of-concept, multidis...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Bijman, Debasish Banerjee, Lisa Anderson, Nicholas M P Annear, Giuseppe Rosano, Irina Chis Ster, Ella Tumelty, Rosa Montero, Ashwin Anenden, Jane Nokes, Vasa Gnanapragasam, Mahrukh Ayesha Ali, Sabba Hussain, Isaac Chung, Matthew Sunter, Tristan Williams
Format: Article
Language:English
Published: BMJ Publishing Group 2025-04-01
Series:BMJ Open Quality
Online Access:https://bmjopenquality.bmj.com/content/14/2/e002984.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850123197206233088
author Laura Bijman
Debasish Banerjee
Lisa Anderson
Nicholas M P Annear
Giuseppe Rosano
Irina Chis Ster
Ella Tumelty
Rosa Montero
Ashwin Anenden
Jane Nokes
Vasa Gnanapragasam
Mahrukh Ayesha Ali
Sabba Hussain
Isaac Chung
Matthew Sunter
Tristan Williams
author_facet Laura Bijman
Debasish Banerjee
Lisa Anderson
Nicholas M P Annear
Giuseppe Rosano
Irina Chis Ster
Ella Tumelty
Rosa Montero
Ashwin Anenden
Jane Nokes
Vasa Gnanapragasam
Mahrukh Ayesha Ali
Sabba Hussain
Isaac Chung
Matthew Sunter
Tristan Williams
author_sort Laura Bijman
collection DOAJ
description Hospital admissions to treat fluid overload are common in patients with both heart failure and chronic kidney disease (CKD-HF). This is a population with high levels of frailty. Recurrent hospital admissions are costly to both patients and healthcare systems. We designed a proof-of-concept, multidisciplinary quality improvement project to deliver at-home subcutaneous furosemide to treat fluid overload in patients with CKD-HF. This project involved collaboration between a hospital, community remote monitoring hub and hospital-at-home team, including general practitioners, secondary care physicians, nurses and pharmacists. Patients were considered suitable for the intervention if they had CKD-HF, fluid overload and were haemodynamically stable. Following review, suitable patients were treated at-home with 80 mg subcutaneous furosemide over 5 hours, for 5 days. This was administered by the hospital-at-home team in liaison with hospital specialists, with continuous patient monitoring provided by the remote monitoring hub. Renal function and weight were assessed daily. Following treatment, patients were reviewed by the secondary-care team to adjust their maintenance medications. Data collected and analysed included daily weights, renal function and observations, as well as the number of hospitalisations and/or death at 30 days following the intervention. 10 patients successfully completed treatment. All potentially required hospitalisation at baseline and all avoided hospitalisation during the 5-day course of subcutaneous furosemide. One patient was admitted to the hospital following their final hospital review, and two patients were hospitalised for 4 and 14 days respectively, after their final dose of subcutaneous furosemide. Renal function and potassium did not significantly change throughout the treatment. No major safety concerns were identified. Patients welcomed the intervention. This quality improvement project demonstrates that it is logistically feasible, with primary care collaboration, to treat fluid overload in patients with CKD-HF at-home using subcutaneous furosemide.
format Article
id doaj-art-a38f26cd7f5446a48fdbbc79ba79e398
institution OA Journals
issn 2399-6641
language English
publishDate 2025-04-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open Quality
spelling doaj-art-a38f26cd7f5446a48fdbbc79ba79e3982025-08-20T02:34:39ZengBMJ Publishing GroupBMJ Open Quality2399-66412025-04-0114210.1136/bmjoq-2024-002984Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement projectLaura Bijman0Debasish Banerjee1Lisa Anderson2Nicholas M P Annear3Giuseppe Rosano4Irina Chis Ster5Ella Tumelty6Rosa Montero7Ashwin Anenden8Jane Nokes9Vasa Gnanapragasam10Mahrukh Ayesha Ali11Sabba Hussain12Isaac Chung13Matthew Sunter14Tristan Williams15St George’s University Hospitals NHS Foundation Trust, London, England, UKSchool of Health & Medical Sciences, St George’s University of London, London, London, UKCardivascular Sciences, St George’s University of London, London, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKSchool of Health & Medical Sciences, St George’s University of London, London, London, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKHospital At Home, London, UKCentral London Community Healthcare NHS Trust, London, London, UKNHS England London, London, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKSt George’s University Hospitals NHS Foundation Trust, London, England, UKHospital admissions to treat fluid overload are common in patients with both heart failure and chronic kidney disease (CKD-HF). This is a population with high levels of frailty. Recurrent hospital admissions are costly to both patients and healthcare systems. We designed a proof-of-concept, multidisciplinary quality improvement project to deliver at-home subcutaneous furosemide to treat fluid overload in patients with CKD-HF. This project involved collaboration between a hospital, community remote monitoring hub and hospital-at-home team, including general practitioners, secondary care physicians, nurses and pharmacists. Patients were considered suitable for the intervention if they had CKD-HF, fluid overload and were haemodynamically stable. Following review, suitable patients were treated at-home with 80 mg subcutaneous furosemide over 5 hours, for 5 days. This was administered by the hospital-at-home team in liaison with hospital specialists, with continuous patient monitoring provided by the remote monitoring hub. Renal function and weight were assessed daily. Following treatment, patients were reviewed by the secondary-care team to adjust their maintenance medications. Data collected and analysed included daily weights, renal function and observations, as well as the number of hospitalisations and/or death at 30 days following the intervention. 10 patients successfully completed treatment. All potentially required hospitalisation at baseline and all avoided hospitalisation during the 5-day course of subcutaneous furosemide. One patient was admitted to the hospital following their final hospital review, and two patients were hospitalised for 4 and 14 days respectively, after their final dose of subcutaneous furosemide. Renal function and potassium did not significantly change throughout the treatment. No major safety concerns were identified. Patients welcomed the intervention. This quality improvement project demonstrates that it is logistically feasible, with primary care collaboration, to treat fluid overload in patients with CKD-HF at-home using subcutaneous furosemide.https://bmjopenquality.bmj.com/content/14/2/e002984.full
spellingShingle Laura Bijman
Debasish Banerjee
Lisa Anderson
Nicholas M P Annear
Giuseppe Rosano
Irina Chis Ster
Ella Tumelty
Rosa Montero
Ashwin Anenden
Jane Nokes
Vasa Gnanapragasam
Mahrukh Ayesha Ali
Sabba Hussain
Isaac Chung
Matthew Sunter
Tristan Williams
Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement project
BMJ Open Quality
title Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement project
title_full Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement project
title_fullStr Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement project
title_full_unstemmed Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement project
title_short Domiciliary subcutaneous furosemide in patients with CKD and HF: a quality improvement project
title_sort domiciliary subcutaneous furosemide in patients with ckd and hf a quality improvement project
url https://bmjopenquality.bmj.com/content/14/2/e002984.full
work_keys_str_mv AT laurabijman domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT debasishbanerjee domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT lisaanderson domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT nicholasmpannear domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT giusepperosano domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT irinachisster domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT ellatumelty domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT rosamontero domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT ashwinanenden domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT janenokes domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT vasagnanapragasam domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT mahrukhayeshaali domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT sabbahussain domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT isaacchung domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT matthewsunter domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject
AT tristanwilliams domiciliarysubcutaneousfurosemideinpatientswithckdandhfaqualityimprovementproject